Eledon Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on January 7, 2021, covering events that occurred on December 31, 2020. The registrant, Eledon Pharmaceuticals, Inc. (formerly Novus Therapeutics, Inc.), is a Delaware corporation with its principal executive offices in Irvine, California. The company's common stock trades on the Nasdaq Capital Market under the symbol "ELDN."
Key Financial Metrics and Capital Structure
The filing does not provide revenue, profit, cash flow, margin, or debt metrics. The report focuses exclusively on a capital restructuring event involving unregistered sales of equity securities. Following the transactions reported, the company's capital structure includes:
- Common Stock Outstanding: 14,306,614 shares
- Series X Convertible Preferred Stock: 6,203.98 shares outstanding
- Conversion Rights: The Series X Preferred Stock is convertible into 344,663 shares of Common Stock (after rounding).
Material Changes
On December 31, 2020, the Company executed two exchange agreements with specific stockholders (Biotechnology Value Fund entities and Cormorant Global Healthcare Master Fund, LP):
- Series X Exchange: Stockholders exchanged 344,666 shares of Common Stock for 6,203.98 shares of Series X Convertible Preferred Stock.
- Warrant Exchange: Stockholders exchanged 509,117 shares of Common Stock for pre-funded warrants to purchase an aggregate of 509,117 shares of Common Stock at a nominal exercise price.
These securities were issued without registration under the Securities Act of 1933, relying on the exemption contained in Section 3(a)(9).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No specific risks or contingencies are detailed in the text of this report, other than the standard disclosure that the description of the Exchange Agreements is qualified by reference to the full text of the agreements filed as exhibits.
Key Facts for Investor Verification
- Verify the terms of the Series X Convertible Preferred Stock, including dividend rights, liquidation preferences, and conversion mechanics, by reviewing Exhibit 10.1.
- Confirm the exercise price and expiration terms of the pre-funded warrants issued in the Warrant Exchange by reviewing Exhibit 10.2.
- Assess the impact of the 853,783 shares of Common Stock removed from circulation (344,666 + 509,117) on the company's total share count and potential dilution upon conversion or exercise.
- Confirm the identity and ownership percentage of the "Exchanging Stockholders" to understand potential voting control shifts.